UY26595A1 - LOW DOSE USE USE FORMULATIONS - Google Patents

LOW DOSE USE USE FORMULATIONS

Info

Publication number
UY26595A1
UY26595A1 UY26595A UY26595A UY26595A1 UY 26595 A1 UY26595 A1 UY 26595A1 UY 26595 A UY26595 A UY 26595A UY 26595 A UY26595 A UY 26595A UY 26595 A1 UY26595 A1 UY 26595A1
Authority
UY
Uruguay
Prior art keywords
low dose
formulations
entecavir
hepatitis
treatment
Prior art date
Application number
UY26595A
Other languages
Spanish (es)
Inventor
Richard J Colonno
Omar L Sprockel
Abozer Harianawala
Divyakant Desai
Michael G Fakes
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22681972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY26595(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26595A1 publication Critical patent/UY26595A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones que contienen una dosis baja de entecavir administradas en una base diaria para tratar una infección y/o co-infecciones del virus de la hepatitis B. Se proporcionan formulaciones para la administración oral de un entecavir de dosis baja. Otras sustancias farmacéuticas activas pueden ser incluidas en la composición de entecavir o pueden ser administradas separadamente para el tratamiento de la infección del virus de la hepatitis B o para el tratamiento de pacientes co-infectadosThe present invention relates to compositions containing a low dose of entecavir administered on a daily basis to treat an infection and / or co-infections of the hepatitis B virus. Formulations for oral administration of a low dose entecavir are provided. Other pharmaceutical active substances can be included in the composition of entecavir or can be administered separately for the treatment of hepatitis B virus infection or for the treatment of co-infected patients.

UY26595A 2000-02-29 2001-02-23 LOW DOSE USE USE FORMULATIONS UY26595A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18567200P 2000-02-29 2000-02-29

Publications (1)

Publication Number Publication Date
UY26595A1 true UY26595A1 (en) 2001-09-28

Family

ID=22681972

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26595A UY26595A1 (en) 2000-02-29 2001-02-23 LOW DOSE USE USE FORMULATIONS

Country Status (4)

Country Link
CN (5) CN1310999A (en)
HK (1) HK1040196A1 (en)
UY (1) UY26595A1 (en)
ZA (1) ZA200205900B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1732944B (en) * 2005-09-02 2013-05-08 海南中和药业有限公司 Entecavir dispersible tablet and its preparation process
CN1820744B (en) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 Oseltamivir phosphate granula and its preparing method
CN101244260B (en) * 2007-02-14 2011-12-28 成都地奥九泓制药厂 Combined medicament for treating chronic hepatitis B
CN101371841A (en) * 2007-08-23 2009-02-25 浙江医药股份有限公司新昌制药厂 Crystallization type Entecavir formulation as well as preparation method and use thereof
CN102578564A (en) * 2011-11-01 2012-07-18 江苏江山制药有限公司 Preparation method for rapid-disintegrating directly-pressed particle mannitol preparation
CN102416003A (en) * 2011-12-08 2012-04-18 南京优科生物医药有限公司 Method for preparing entecavir tablets
CN102552210B (en) * 2012-01-10 2013-12-11 四川海思科制药有限公司 Entecavir capsule and preparation method thereof
KR101285008B1 (en) * 2012-04-18 2013-07-10 제일약품주식회사 A method for preparing oral formulation of low dose entecavir
CA3225480A1 (en) * 2015-02-01 2016-08-04 Syros Pharmaceuticals, Inc. High surface-area lyophilized compositions comprising arsenic for oral administration in patients
CN112535736B (en) * 2020-12-14 2023-08-29 石家庄四药有限公司 Entecavir composition and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.

Also Published As

Publication number Publication date
ZA200205900B (en) 2004-03-29
CN1310999A (en) 2001-09-05
CN1813753A (en) 2006-08-09
CN102772413A (en) 2012-11-14
CN101444511A (en) 2009-06-03
CN101385732A (en) 2009-03-18
CN1813753B (en) 2010-04-07
CN101444511B (en) 2013-01-02
HK1040196A1 (en) 2002-05-31
CN1813753C (en)

Similar Documents

Publication Publication Date Title
BRPI0108435B8 (en) formulation and use of low-dose entecavir
AR035927A1 (en) LACTAMA COMPOUND (N) - ((S) -2-HIDROXI-3-METHYLBUTIRILE) -1- (L-ALANINIL) - (S) -1-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO -2H-3-BENZAZEPIN-2-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE FOR THE INHIBITION OF THE B-AMYLOID PEPTIDE RELEASE AND / OR ITS SYNTHESIS THAT USES IT AND ITS USE FOR THE FABR
ATE269056T1 (en) HIGHLY EFFECTIVE MEDICINAL COMPOSITIONS CONTAINING DIHYDROERGOTAMIN
CR8352A (en) PHARMACEUTICAL FORMULATIONS, PROCEDURES AND DOSAGE GUIDELINES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CU23468B7 (en) DOSAGE FORM OF PRAMIPEXOL IN A SINGLE DAILY DOSE
CR6458A (en) VALDECOXIB COMPOSITIONS
DE60115029D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABIDIOL DERIVATIVES
BR0108730A (en) System, device and method for administering a drug, mouthpiece of a drug delivery device, device for administering multiple unit doses of a drug, methods for preparing a drug delivery system and a drug formulation and for treatment of a patient who needs multiple doses of a drug, drug formulation and multiparticulates
AR012614A1 (en) A PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF A SUSCEPTIBLE VIRAL INFECTION OF TREATMENT WITH ALPHA INTERFER, A METHOD FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, FOR THE MANUFACTURE OF A MEDICINE
HRP20030046B1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
RU2007104774A (en) COMBINATION OF ANTI-HIV REVERSE TRANSCRIPTASE AND PROTEASES INHIBITORS
WO2006044968A3 (en) Combination therapy for treating viral infections
ES2721899T3 (en) Pharmaceutical compositions comprising fentanyl for intranasal administration
ATE324886T1 (en) SOLID MEDICINAL COMPOSITION CONTAINING 4'-CYANO-TRIFLUORO-3-(4-FLUOROPHENYLSULPHONYL) -2-HYDROXY- 2-METHYLPROPIONO- M TOLUIDIDE AND PVP
DE50203456D1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
UY26595A1 (en) LOW DOSE USE USE FORMULATIONS
KR970061244A (en) Pharmaceutical composition for treating dementia
AR035946A1 (en) PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES
ES2175663T3 (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MILTEPHOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LESHMANIASIS.
BR0109747A (en) Use of 5- (2-pyrazinyl) -4-methyl-1-2-dithiol-3-thione (oltipraz) as a medicine, pharmaceutical composition for the prevention and treatment of hepatic fibrosis progression, use of 5- (2- pyrazinyl) -4-methyl-1,2-dithiol-3-thione and method for the prevention and treatment of fibrosis progression and liver cirrhosis
HUP0003546A2 (en) Compositions for administering taxanes orally to human patients
AR036877A1 (en) PHARMACEUTICAL FORMULATION
AR014082A1 (en) ORAL SERTRALINE CONCENTRATE
BR0009875A (en) Use of n-acetylcysteine for the preparation of a drug suitable for intravenous administration to prevent oxidative load in patients who have undergone dialysis

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20141023

VENC Patent expired

Effective date: 20210223